Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Riluzole [USAN:USP:INN:BAN]
RN: 1744-22-5
UNII: 7LJ087RS6F
InChIKey: FTALBRSUTCGOEG-UHFFFAOYSA-N

Note

  • A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Molecular Formulas

  • C8-H5-F3-N-O-S
  • C8-H5-F3-N2-O-S

Molecular Weight

  • 234.2005
 

Classification Codes

  • Amyotrophic Lateral Sclerosis Treatment
  • Anticonvulsants
  • Central Nervous System Agents
  • Drug / Therapeutic Agent
  • Excitatory Amino Acid Agents
  • Excitatory Amino Acid Antagonists
  • Neuroprotective Agents
  • Neurotransmitter Agents
  • Protective Agents
  • Treatment of Amyotrophic Lateral Sclerosis

Names and Synonyms

Name of Substance

  • Riluzole
  • Riluzole [USAN:USP:INN:BAN]

MeSH Heading

  • Riluzole

Synonyms

  • 2-Amino-6-(trifluoromethoxy)benzothiazole
  • 2-Benzothiazolamine, 6-(trifluoromethoxy)-
  • Amino-2 trifluoromethoxy-6 benzothiazole
  • Amino-2 trifluoromethoxy-6 benzothiazole [French]
  • Rilutek
  • Riluzol
  • Riluzol [INN-Spanish]
  • Riluzole
  • Riluzolum
  • Riluzolum [INN-Latin]
  • RP 54274
  • UNII-7LJ087RS6F

Systematic Names

  • 2-Benzothiazolamine, 6-(trifluoromethoxy)-
  • Benzothiazole, 2-amino-6-trifluoromethoxy-

Registry Numbers

CAS Registry Number

  • 1744-22-5

FDA UNII

  • 7LJ087RS6F

System Generated Number

  • 0001744225

Structure Descriptors

InChI

1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)

InChIKey

FTALBRSUTCGOEG-UHFFFAOYSA-N

Smiles

s1c(nc2c1cc(cc2)OC(F)(F)F)N

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
mouse LD50 intraperitoneal 46mg/kg (46mg/kg)   European Patent Application. Vol. #50551,
mouse LD50 intravenous 34500ug/kg (34.5mg/kg) BEHAVIORAL: ATAXIA

BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 41, Pg. 1973, 1999.
mouse LD50 oral 67mg/kg (67mg/kg)   European Patent Application. Vol. #50551,
rat LD50 intravenous 22mg/kg (22mg/kg) BEHAVIORAL: MUSCLE WEAKNESS

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 41, Pg. 1973, 1999.
rat LD50 oral 45mg/kg (45mg/kg) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: ATAXIA
Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 41, Pg. 1973, 1999.